Chemogenomics in Drug Discovery

Zusatztext

Chemogenomics brings together the most powerful concepts in modern chemistry and biology, linking combinatorial chemistry with genomics and proteomics.<br> This first reference devoted to the topic covers all stages of the early drug discovery process, from target selection to compound library and lead design.<br> With the combined expertise of 20 research groups from academia and leading pharmaceutical companies, this is a must-have for every drug developer and medicinal chemist applying the powerful methods of chemogenomics to speed up the drug discovery process.

Autorenportrait

Hugo Kubinyi studied chemistry in Vienna, Austria. After his Ph.D. thesis at the Max Planck Institute of Biochemistry in Munich he continued as a PostDoc at the German Cancer Research Centre in Heidelberg. In 1966 he joined Knoll AG, later a subsidiary of BASF AG, and in 1985 he moved to BASF AG. Since 1987, until his retirement in summer 2001, he was responsible for the Molecular Modelling, Protein Crystallography and Drug Design group of BASF, since early 1998 also for Combinatorial Chemistry in the Life Sciences.<br /> He is Professor of Pharmaceutical Chemistry at the University of Heidelberg, former Chair of The QSAR and Modelling Society, and IUPAC Fellow. From his scientific work resulted five books on QSAR, 3D QSAR, and Drug<br /> Design (the German book "Wirkstoffdesign" received the 1999 Book Award of the FCI, Association of Chemical Industry) and about 90 publications.<br /> He is a member of several Scientific Advisory Boards, coeditor of the Wiley-VCH book series "Methods and Principles in Medicinal Chemistry", and member of the Editorial Boards of several scientific journals.<br /><br /> Gerhard Müller graduated in Organic Chemistry from the University of Frankfurt/Main (Germany) and received his PhD in 1992 at the Technical University of Munich. After two years in the Medicinal Chemistry department of Glaxo Verona (Italy), he joined the central research facility of the Bayer AG, Leverkusen. From 1998 onwards he was project manager of a target family approach in medicinal chemistry. From 2001 to 2003 he headed the chemistry section of Organon's Lead Discovery Unit in Oss (The Netherlands). Since summer 2003, Gerhard Müller is the chief scientific officer of the Munich-based biotech company Axxima Pharmaceuticals AG.<br />

Weitere Details